Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford’s first precision prevention cancer trial in people with Li Fraumeni Syndrome has opened to recruitment

People with Li Fraumeni Syndrome (LFS) have a 70-90% lifetime risk of developing a wide range of cancers. The Metformin in Li Fraumeni Syndrome (MILI) trial will evaluate whether the existing type 2 diabetes drug metformin can prevent or delay the emergence of cancer in people with LFS.

Co-funded by the National Institute for Health and Care Research, the Medical Research Council and Cancer Research UK, this trial will recruit 200 participants and have an embedded research project investigating the mechanism of how metformin may prevent or delay cancer. This will help researchers understand more about how cancer may be prevented in the general population.

The study protocol has been published in the Trials journal.

The first patient recruited MILI, Abbi Ritson has spoken about her experience of taking part in the trial.


It gives people like me hope for the future. If it works, there’s a chance that we could be taking this drug and it could make a difference. - Abbi Ritson, MILI trial participant

MILI will also tell us a lot about the biology of how this treatment works and how cancer forms in people with LFS. These are really important questions that we’ve never been able to answer - Professor Sarah Blagden, Chief Investigator of the MILI trial

Watch more in this feature on ITV news on 25th January 2024.